

Appendix Table F151. Nonsignificant differences in comparative effectiveness of oxybutynin when compared to nonpharmacological treatments (results from individual randomized controlled clinical trials)

Reference	Outcome	Active treatment	Control treatment	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)
Karademir, 2005 ³²³	Cured from urge incontinence	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	3/21	3/23	1.10 (0.25; 4.84)	0.01 (-0.19; 0.22)
Karademir, 2005 ³²³	Decrease in symptoms of frequency	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	8/21	10/22	0.84 (0.41; 1.71)	-0.07 (-0.37;0.22)
Karademir, 2005 ³²³	Decrease in symptoms of urgency	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	10/21	13/22	0.81 (0.46; 1.42)	-0.12 (-0.41 ;0.18)
Karademir, 2005 ³²³	Decrease in symptoms of urge incontinence	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA	Stoller afferent neurostimulation with frequency 20 Hz and amplitude 0.5-10 mA combined with 5 mg of oral oxybutynin hydrochloride	15/21	20/22	0.79 (0.58; 1.06)	-0.20 (-0.42; 0.03)
Burgio, 2010 ²⁴⁷	Completely satisfied with treatment progress	Pelvic Floor Muscle training + Urge suppression techniques + Oxybutynin	Oxybutynin	25/32	28/32	0.89 (0.71;1.12)	-0.09 (-0.28; 0.10)
Burgio, 2010 ²⁴⁷	Perceived improvement: much better	Pelvic Floor Muscle training + Urge suppression techniques + Oxybutynin	Oxybutynin	25/32	29/32	0.86 (0.70; 1.07)	-0.13 (-0.30;0.05)
Goode, 2002 ²⁹⁴	Self reported improvement in UI	Four sessions (over 8 weeks) of biofeedback-assisted behavioral training by nurse practitioners.	2.5 mg of oxybutynin chloride 3 times/day, dose adjustments from minimum 2.5 mg/ day to a maximum 5.0 mg 3 times/day	27/33	27/35	1.06 (0.83; 1.35)	0.05 (-0.15; 0.24)